top of page
32200c5c-7c4c-438f-a9df-3119a2398bf2.png
Autchmaber1.png
ai-cvd.png
AI-CVD Summary
Coronary Calcification
816_aicvd (8)_4_edited.jpg
‌ Aortic Calcification
ٍEpicardial Fat _edited.jpg
Epicardial Fat
816_aicvd (8)_5_edited.jpg
Cardiac Chambers
816_aicvd (8)_7_edited.jpg
Aorta & PA Size
816_aicvd (8)_10_edited.jpg
Lung LAI
816_aicvd (8)_9_edited.jpg
Lung HAI
816_aicvd (8)_11_edited.jpg
Liver Fat
816_aicvd (8)_12_edited.jpg
Muscle & Visceral Fat
816_aicvd (8)_13_edited.jpg
Bone Density
f055739f-1956-41a1-8156-cda95d1fea9f.png
AI-CVD Bundle
Muscle and Fat Analysis.png
Liver Attenuation.png
Cardiac Chambers Volumetry.png
ٍEpicardial Fat .png
Bone Mineral Density (BMD) .png
coronaryArteryCalcification.png
Lung Density Report- High Attenuation Index.png
Thoracic Aorta and Pulmonary Artery Sizing .png
Aortic Wall Aortic and Mitral Valve Report.png
Lung Density Report- Low Attenuation Index.png
AI-CVD--.png
Frame 1000008286.png
Frame 1000008286.png

New details on the link between CVD and cancer, from a study of 27M patients

Apr 24, 2023
2 min read

Michael Walter

Individuals with cardiovascular disease (CVD) face a much higher risk of developing cancer than those without CVD, according to new findings published in JACC: CardioOncology.[1] The cancer risk is even higher, researchers noted, for individuals with atherosclerotic CVD.


“CVD and cancer continue to represent the two leading causes of death in the United States,” wrote first author Caitlin F. Bell, MD, a fellow in the department of medicine at Stanford University School of Medicine, and colleagues. “These diseases share a multitude of risk factors, underscored by the reduction in mortality from both conditions when patients adhere to cardiovascular risk reduction guidelines. However, it is becoming increasingly clear that the two diseases may have a more complicated relationship, including shared pathophysiological mechanisms that extend beyond traditional risk factors.”


The group’s analysis included data from a whopping 27.2 million cancer-free patients. There was a minimum of three years of follow-up data available for each patient.


Overall, the group found, patients diagnosed with CVD were 12% more likely to develop cancer. Patients with atherosclerotic CVD, meanwhile, faced a higher cancer risk than patients with other forms of CVD.


In addition, patients with atherosclerotic CVD had “a significantly higher risk” of “cancers of the lung, bladder, colon, head and neck, liver, prostate, pancreas, and kidney, as well as lymphoma, leukemia and other hematologic malignancies” than patients with nonatherosclerotic CVD.


Why is there such a link between these two leading causes of death? The authors wrote that, yes, shared risk factors do appear to play a role, but that may just be the tip of the iceberg.

“It is enticing to hypothesize that these links between CVD and specific cancer subtypes are mediated through shared biological processes (eg, inflammation, metabolic adaptations, etc.),” they wrote.


Research are actively investigating this possibility, but it is still far too early to make any judgements. Bell et al. also wrote that there is some evidence of “pathophysiological overlap between cancer and CVD independent of shared traditional risk factors.”


“Genome-wide association studies have shown that the most important commonly inherited genetic variant associated with atherosclerosis resides in a well-known cancer locus at chromosome 9p21, rather than in a gene that regulates traditional CV risk factors,” they wrote. “Inflammation and immune cell activation have also been linked to both conditions.”


The authors concluded by calling for even more research into this relationship between CVD and cancer. It is important, for example, to learn if certain groups of CVD patients should be exposed to cancer prevention tools or screening protocols.


Click here to read the full study in JACC: CardioOncology, a publication of the American College of Cardiology.




Comments


Ready to Unlock the Value in Your CT Scans?

Join leading healthcare providers using AI-CVD to save lives and increase revenue, and lead the future of preventive cardiology.

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Youtube

2450 Holcombe Blvd
TMC Innovations
Houston, TX 77021

aicvd patent_edited_edited.jpg
ISO LOGO_edited.png
autoliver patent.png

©2026 HeartLung Corporation. All Rights Reserved. US Patent Nos US9119590*, US10695022, US11610686, US18167691, US20240115224, and Patents Pending. AI-CVD, AI-CAC, AutoBMD, AutoCAC, AutoChamber and other trademarks shown on this website are protected under intellectual property rights of HeartLung Corporation in the United States.

bottom of page